GO
Loading...

Enter multiple symbols separated by commas

Sanofi SA

More

  • LONDON, Jan 12- European equities rebounded on Monday, led by airlines and auto stocks after positive updates by Continental and Lufthansa. Brent crude dropped below $49 a barrel on Monday, around its lowest since April 2009, hit by a global supply glut. "The tremendous oil price collapse is not adequately reflected in the airlines' share prices in my view," said...

  • *Peugeot buoyed by broker upgrade. LONDON, Jan 12- European equities gained on Monday, led by rising healthcare stocks, after Shire agreed to buy NPS Pharmaceuticals for $5.2 billion and Roche also struck a deal. Chemicals shares also performed well after U.S. investment bank Citigroup upgraded several European chemicals companies, including BASF.

  • Rise in healthcare stocks lifts European equities Monday, 12 Jan 2015 | 3:20 AM ET

    LONDON, Jan 12- A rise in healthcare shares, following renewed signs of industry consolidation after Shire Plc agreed to buy NPS Pharmaceuticals for $5.2 billion, lifted European equities on Monday. "The Shire deal is likely to mean that there will be no fresh bid speculation coming through on Shire itself, although the ongoing consolidation within the industry...

  • Midday movers: Wynn Resorts, Chevron, Crocs & more Friday, 9 Jan 2015 | 1:15 PM ET
    Wall Street subway station NYSE

    Some of Friday's midday movers:

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Jan 6- KaloBios Pharmaceuticals Inc said it would discontinue the development of its drug for lung infections in cystic fibrosis patients after it failed in a mid-stage study, sending the company's shares down 62 percent in extended trading. The company said its drug, KB001-A, did not extend the time before cystic fibrosis patients had to take antibiotics for...

  • KaloBios drops lung infection drug, shares plunge Tuesday, 6 Jan 2015 | 4:35 PM ET

    Jan 6- KaloBios Pharmaceuticals Inc said it would discontinue the development of its drug for lung infections in cystic fibrosis patients after it failed in a mid-stage study, wiping off more than half of its market value. The drug, KB001-A, failed to buy patients more time before taking antibiotics for their worsening respiratory tract symptoms.

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Cramer Remix: Here’s what the Fed did Wednesday, 17 Dec 2014 | 7:06 PM ET
    Jim Cramer on Mad Money.

    The market may have rallied, but "Mad Money" host Jim Cramer thinks that’s just the beginning of Yellen’s impact.

  • Lightning Round: Good stock with a good yield Wednesday, 17 Dec 2014 | 6:57 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • UPDATE 1-Pozen says FDA rejects lead drug again Wednesday, 17 Dec 2014 | 8:18 AM ET

    Dec 17- Pozen Inc said two versions of its experimental heart drug were rejected for the second time by the U.S. Food and Drug Administration, which again cited deficiencies in the manufacturing plant of a supplier of an active ingredient. Pozen's shares fell nearly 23 percent to $6.99 in premarket trading on Wednesday. Pozen, which first received the rejection...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • 'Kickback' flak: Sanofi's caseload grows bigger Friday, 5 Dec 2014 | 4:37 PM ET
    A Sanofi lab worker packages vaccines against the flu.

    Drug giant Sanofi is juggling legal and regulatory issues surrounding three cases involving alleged payments or inducements to medical providers.

  • Ponte worked in Sanofi's Bridgewater, New Jersey, office reviewing contracts for legal compliance, according to the lawsuit. In March 2013, she discovered that nine contracts paying $34 million to accounting firm Deloitte LLP and consulting firm Accenture Plc were actually covers for kickbacks, the lawsuit said. Deloitte and Accenture are not defendants in...

  • LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. Bidders, who had been hoping to clinch a deal before the end of the year,...